Literature DB >> 32598185

Clinico-radiological monitoring strategies in patients with metastatic breast cancer: a real-world study.

Marta Bonotto1, Debora Basile1,2, Lorenzo Gerratana1,2, Michele Bartoletti1,2, Camilla Lisanti1,2, Giacomo Pelizzari1,2, Maria Grazia Vitale1,2, Valentina Fanotto1,2, Elena Poletto1, Alessandro Marco Minisini1, Stefania Russo1, Claudia Andreetta1, Mauro Mansutti1, Gianpiero Fasola1, Fabio Puglisi2,3.   

Abstract

Aim: A monitoring strategy for metastatic breast cancer patients (M-MBC) has been little studied. Materials & methods: This retrospective study analyzed a consecutive cohort of 382 MBC patients to analyze different M-MBC strategies to identify factors influencing intensive M-MBC.
Results: Elevated baseline serum tumor markers (STM) was the strongest factor associated with increased use of STM tests. Having more frequent oncology office visits was associated with more intensive chemotherapy/magnetic resonance imaging (MRI) using. Increased use of imaging tests was associated with participation to clinical trial. Single and elderly patients were less likely to have frequent testing. Having clinically measurable disease was less likely to have more intensive M-MBC.
Conclusion: STM testing and scans were frequently ordered in M-MBC. In the present study, strategies are little influenced by clinico-pathological characteristics.

Entities:  

Keywords:  breast cancer, determinants of monitoring; metastatic breast cancer; monitoring breast cancer; monitoring strategies

Mesh:

Substances:

Year:  2020        PMID: 32598185     DOI: 10.2217/fon-2020-0020

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  1 in total

1.  Association of guideline-concordant initial systemic treatment with clinical and economic outcomes among older women with metastatic breast cancer in the United States.

Authors:  Ami Vyas; Tyler Mantaian; Shweta Kamat; Sobha Kurian; Stephen Kogut
Journal:  J Geriatr Oncol       Date:  2021-06-05       Impact factor: 3.929

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.